New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT01375829
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more cancer cells. A total of 22 participants were enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?